Changes in the Profile and Care of HIV-HCV Seropositive Patients in Two Cross-Sectional Surveys in France (2006 and 2013)
Patrice Cacoub1*-4, Arielle Elmaleh-Sachs1,4, Isabelle Poizot-Martin5, Cécile Goujard6, Patrick Miailhes7, Philippe Morlat8, Julie Chas9, Isabelle Goderel10,Philippe Halfon11, François Caron12, David Rey13, François Boue14, Anne Simon15, Stanislas Pol16, Eric Rosenthal17 and The GERMIVIC Study Group18
- *Corresponding Author:
- Patrice Cacoub
Département de Médecine Interne
et d’Immunologie Clinique
Paris, F-75013, France
E-mail: [email protected]
Received date: September 22, 2014; Accepted date: November 24, 2014; Published date: November 28, 2014
Citation: Cacoub P, Elmaleh-Sachs A, Poizot-Martin I, Goujard C, Miailhes P, et al. (2014) Changes in the Profile and Care of HIV-HCV Seropositive Patients in Two Cross-Sectional Surveys in France (2006 and 2013). J AIDS Clin Res 5:388. doi:10.4172/2155-6113.1000388
Copyright: © 2014 Cacoub P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aim: To analyze HCV care and treatment in HIV-HCV coinfected patients and their evolution between 2006 and2013, in France.Patients and
methods: HIV-HCV consecutive seropositive patients were prospectively included in two crosssectional
studies from April 3 to 10, 2006 (n=416) and from April 8 to 15, 2013 (n=342). A standard data collection
form was used.
Results: Patients in 2013 compared to those in 2006 had undetectable HIV viral load and negative HCV viremia more often (82% vs. 69%, and 48% vs. 27%, respectively), with more frequent co-infection by HCV genotype 1 and 4. Liver biopsy was done less frequently (5% vs. 35%). Non-invasive liver damage assessment was done more frequently (42% vs. 22%), using serum biomarkers (37% vs. 67%) or liver-stiffness methods (69% vs. 11%). A sustained virological response to HCV treatment was more frequent (50% vs. 30%). In both surveys, patients who had received HCV treatment compared to those who had never been treated were more often of European origin, had better control of their HIV infection, had more frequent liver damage assessments and were less frequently infected by a genotype 4.
Conclusion: In comparison to 2006, more co-infected patients in 2013 had better control of their HIV infection, had liver damage assessment, received HCV treatment and more frequently had a sustained virological response. New anti-HCV combinations with greater efficacy and less toxicity should soon modify the present picture.